GSK Lowers Vaccine Sales Forecast Amid Shingrix Inventory ShiftsIn-depth Insight: Shingrix and Arexvy are GSK's two most notable products. Both are expected to drive growth, so the company’s downgrade of its vaccine division forecast stands in contrast to what was otherwise a “better-than-expected and upgraded” quarter.The logo of GSK appears on the side of an office building. Despite a slowdown in sales of its shingles vaccine Shingrix, the company said on July 31, 2024, that it expects overall growth to accelerate. Provided by GSK.Overall, GSK reported sales of £7.9 billion and raised its full-year growth forecast to 7%-9%, up from the previous 5%-7%. The company also increased its sales estimates for its specialty medicines division, which includes lucrative HIV drugs.GSK's share price fell in the second-quarter digital trading on the London and New York stock exchanges.For Shingrix, GSK reported that growth in Europe and other international markets was offset by a quarterly decline in the United States, where the company faces the challenge of convincing harder-to-reach adults to get vaccinated. GSK estimates that 37% of the more than 120 million U.S. adults recommended to receive Shingrix have been vaccinated.GSK expects Shingrix sales to eventually climb to over $4 billion annually, driven by its launch in countries outside the U.S.Arexvy is a newer product and has had a strong start, capturing two-thirds of the market share, surpassing Pfizer's competitor RSV vaccine Abrysvo. RSV infections most commonly occur in the fall and winter in the U.S. and Europe, so sales in the second quarter are expected to decline.Although sales may recover in the second half of the year, the Centers for Disease Control and Prevention recently adjusted its recommendations to place stronger emphasis on adults aged 75 and above, who are more vulnerable to RSV-related illnesses. GSK has been working to expand the use of its vaccine among younger adults aged 50 to 59, for whom the CDC has not yet issued guidance.GSK will also face a new competitor, Moderna's Mresvia, which has recently received approval from the Food and Drug Administration.References:https://www.biopharmadive.com/news/gsk-vaccines-arexvy-rsv-shingrix-second-quarter/722888/To promote the exchange of information in the human and veterinary vaccine industries, and to jointly explore the latest R&D progress, industrialization status, and future development trends in this field,Bio-products Circle collaborates with Clover Conference and ExhibitionWill beAugust 16-17, 2024InSuzhouCo-organized by "The 3rd New Vaccine Development Summit”。We sincerely invite experts, scholars, and entrepreneurs in related fields across China to share in this academic盛会.The relevant matters are hereby notified as follows.Name:2024 3rd New Vaccine Development SummitTime:2024August 16-17 (Friday-Saturday)Location:Suzhou(Hotel Directional Notice)Hosted by:Clover Exhibition, Biopharmaceutical CircleMedia Support:Medicine Space-Time, Antibody Circle, Cell Gene Research CircleConference Fee:Scan the QR code to inquire.Registration Method:ScanQR code below→ Fill in the form → Registration successful (Volunteer registration,No registration fee required, with a certain amount of work tasks to be undertaken.）！
Forward and Share Benefits:Personnel from vaccine development companies, research institutions, and regulatory agencies,Top 30Participants who forward and share the conference information can attend the conference for free (excluding meals). After registration, scan the QR code below to add the staff's WeChat.，Send the screenshot only.
After the organizing committee receives the registration information, they will conduct an initial screening based on the information and further communicate with registrants for confirmation to extend precise invitations. Those who pass the strict review will have the opportunity to join the conference WeChat group.Conference Agenda
Confirmed Speaker
Scan the WeChat QR code, add the editor of the Biological Products Circle, and those who meet the requirements can join.Biological Products WeChat Group! Please indicate: Name + Research Direction! EditionAuthoritySoundBrightAll reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted can contact us at (cbplib@163.com), and we will delete the content immediately. All articles represent the views of the author and do not represent the position of this website.
